BPDCN International Registry shared a post on LinkedIn:
“Genomics and clinical experience in older adults have shaped much of what we know about BPDCN-but pediatric and AYA cases behave differently and remain underreported.
Our next BPDCN Paper Of The Day focuses on how BPDCN presents, behaves, and can be treated in children, adolescents, and young adults, including the role of novel targeted therapies.
Paper #4 – Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies.
This review summarizes 20 years of reported pediatric/AYA BPDCN, highlighting that disease can be widely disseminated at presentation yet may be less biologically aggressive than in older adults. It also discusses how ALL‑like regimens, risk-adapted use of allo‑HCT, and emerging CD123‑directed and other novel agents are being integrated into treatment for younger patients.
The BPDCN International Registry (NCT05430971) is actively enrolling centers worldwide, including pediatric and AYA cases. Interested in contributing real‑world data?bpdcn@immonc.org.”
Title: Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies
Authors: Branko Cuglievan, Jeremy Connors, Jiasen He, Sajad Khazal, Sireesha Yedururi, Julia Dai, Sofia Garces, Andres E. Quesada, Michael Roth, Miriam Garcia, David McCall, Amber Gibson, Dristhi Ragoonanan, Demetrios Petropoulos, Priti Tewari, Cesar Nunez, Kris M. Mahadeo, Sarah K. Tasian, Adam J. Lamble, Anna Pawlowska, Danielle Hammond, Abhishek Maiti, Fadi G. Haddad, Jayatsu Senapati, Naval Daver, Naseema Gangat, Marina Konopleva, Soheil Meshinchi, Naveen Pemmaraju
Read the Full Article.
Other articles about BPDCN on OncoDaily.